These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19388726)

  • 1. Spontaneous reports and pharmacogenetics: the role of the pharmacovigilance centre.
    van Puijenbroek E; Conemans J; van Grootheest K
    Drug Saf; 2009; 32(4):357-8. PubMed ID: 19388726
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics and pharmacovigilance.
    Howland RH
    Drug Saf; 2009; 32(3):265-70. PubMed ID: 19338384
    [No Abstract]   [Full Text] [Related]  

  • 3. Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands.
    van Puijenbroek E; Conemans J; van Grootheest K
    Drug Saf; 2009; 32(3):255-64. PubMed ID: 19338383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data.
    De Bruin ML; van Puijenbroek EP; Bracke M; Hoes AW; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):99-105. PubMed ID: 16329159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.
    Jaquenoud Sirot E; van der Velden JW; Rentsch K; Eap CB; Baumann P
    Drug Saf; 2006; 29(9):735-68. PubMed ID: 16944962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting adverse drug reaction reporting: comparison of different approaches.
    Ribeiro-Vaz I; Santos CC; Cruz-Correia R
    Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
    Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
    Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
    Awada Z; Zgheib NK
    Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in Russia: current state of affairs, challenges, and prospects.
    Gildeeva G; Belostotsky A
    Curr Med Res Opin; 2017 Dec; 33(12):2161-2166. PubMed ID: 28562116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronic Reporting Systems in Pharmacovigilance: The Implementation of VigiFlow in Brazil.
    Vogler M; Ricci Conesa H; de Araújo Ferreira K; Moreira Cruz F; Simioni Gasparotto F; Fleck K; Maciel Rebelo F; Kollross B; Silveira Gonçalves Y
    Pharmaceut Med; 2020 Oct; 34(5):327-334. PubMed ID: 32930977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in a genomic era.
    Farahani P; Levine M
    Pharmacogenomics J; 2006; 6(3):158-61. PubMed ID: 16415916
    [No Abstract]   [Full Text] [Related]  

  • 18. Modern methods of pharmacovigilance: detecting adverse effects of drugs.
    Norén GN; Edwards IR
    Clin Med (Lond); 2009 Oct; 9(5):486-9. PubMed ID: 19886114
    [No Abstract]   [Full Text] [Related]  

  • 19. The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice.
    Raschi E; La Placa M; Poluzzi E; De Ponti F
    Br J Dermatol; 2021 Mar; 184(3):581-583. PubMed ID: 33184850
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.